Back to search results

Jornay PM for Adult ADHD Symptoms and Executive Function

This study is looking at how well Jornay PM (methylphenidate hydrochloride extended-release capsules) works for adults with Attention-deficit/Hyperactivity Disorder (ADHD). Jornay PM is a unique medication taken in the evening that starts working in the morning and lasts throughout the day. While it's approved for children, there's no information yet on its effects or best dosage for adults. This trial aims to gather that first information. You might be able to join if you are an adult between 18 and 60 years old with an ADHD diagnosis. The study will measure changes in your ADHD symptoms using a special rating scale at 3 weeks and 10 weeks to see if the medication is effective. The study plans to enroll 30 participants.

Study design
This is an open-label study, meaning you and your doctors will know you are receiving Jornay PM. It plans to include 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your ADHD symptoms will be checked at 3 weeks and again at 10 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06577779

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

Recruiting
PHASE4Ages 18–60InterventionalTreatment
NYU Langone Health
~30 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:Methylphenidate Hydrochloride Extended Release Capsule

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 3
Measured over Baseline, Week 3
+1 more outcome measured

Conditions

Attention-deficit/Hyperactivity Disorder

Explore related trials

Attention Deficit Hyperactivity Disorder

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Lenard Adler, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Terry Leon, MS, RN
[email protected]
646-754-4841
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 3Baseline, Week 3

    The expanded AISRS is an 18-item questionnaire assessing symptoms of adult ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate more severe symptoms of ADHD.

  • Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Score from Baseline to Week 10Baseline, Week 10

    The expanded AISRS is an 18-item questionnaire assessing symptoms of adult ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate more severe symptoms of ADHD.